Pfizer
Pfizer, established in 1849, is a leading global pharmaceutical company headquartered in the United States. Its core business involves the discovery, development, manufacture, and sale of prescription medicines, vaccines, and health care products. Pfizer's extensive portfolio spans various therapeutic areas, focusing on wellness and prevention, as well as treatments and cures for numerous diseases. Notable products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. With approximately 50% of its sales coming from international markets, including significant contributions from emerging markets, Pfizer's global presence is substantial. The company is committed to providing access to safe, effective, and affordable medicines, driven by its purpose to improve patient outcomes and enhance overall health. Pfizer Venture Investments, its corporate venture capital arm, invests in emerging companies developing transformative medicines and technologies to further strengthen its pipeline. Additionally, the Pfizer Foundation, an independent non-profit, supports global health strategies and community involvement through funding and resources.
Top Stages
Caroline Roan
Chief Sustainability Officer | SVP, Global Health and Social Impact | President, The Pfizer
Past deals in Nanotechnology
Resistell
Grant in 2022
Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.
AnTolRx
Series A in 2016
AnTolRx, Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2015. The company specializes in developing novel nanoparticle-based therapies aimed at treating autoimmune diseases. Unlike traditional therapies that broadly suppress the immune system and may lead to severe side effects, AnTolRx's approach focuses on promoting antigen-specific immune tolerance. Their proprietary drug development strategy targets pathogenic immune cells to deliver a unique tolerogenic signal, which helps induce an anti-inflammatory response. This innovative method aims to address the unmet clinical needs in treating conditions such as type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, offering healthcare professionals safer and more effective treatment options without compromising the immune system.
BIND Therapeutics
Acquisition in 2016
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.